Peptide properties are determined by their amino acid composition and sequence. After solid-phase peptide synthesis (SPPS), the cleavage process produces a crude product that contains the desired peptide alongside various impurities, including deletion peptides, truncated peptides, incompletely deprotected peptides, modified peptides, residual reagents, and by-products from cleaved protecting groups. These contaminants must be removed to isolate the final product.
How are peptides purified?
Removal of cytotoxic reagents
During synthesis, cytotoxic reagents (except trifluoroacetic acid, TFA) are removed in the washing steps before final cleavage or during the purification process. This ensures that harmful reagents do not remain in the final peptide.
Purification with RP-HPLC
The standard method for peptide purification is reversed-phase high-performance liquid chromatography (RP-HPLC), using C18-modified silica as the stationary phase and UV detection. In RP-HPLC, the retention of peptides and impurities depends on their hydrophobicity. The purification process begins with polar contaminants being eluted first with aqueous 0.1% TFA. The polarity of the eluent is then gradually reduced by increasing the proportion of acetonitrile (also containing 0.1% TFA). This separates the target peptide from other impurities, which are monitored at 210–220 nm. Fractions containing sufficiently pure target peptide, as determined by analytical HPLC, are pooled and freeze-dried or subjected to additional purification if necessary.
Alternatives and challenges in purification
If standard RP-HPLC methods do not yield sufficient purity, alternate RP-HPLC methods with different solvents or buffers may be used. In some cases, alternative column packing materials might be necessary, especially for less polar peptides. For peptides synthesized in solution, countercurrent distribution (CCD)is often used for purification (see figure 12).
Scalability and lyophilization
Peptide purification can become a bottleneck in large-scale production, especially if the raw peptide quality is poor. To expedite the process, methods like CCD may be more suitable for large-scale synthesis. Once purified, the peptide is obtained as a solution, which is then lyophilized to remove the solvent and produce a fine white powder. While it is not possible to completely remove all water, this does not impact the final product.
Peptides with basic groups
Peptides containing basic groups (such as N-terminus, Arg, Lys, or His) bind to TFA (in Fmoc-SPPS peptides) or acetic acid to form salts. These salts cannot be removed during purification but do not affect the quality of the final peptide.
The Multicolumn Countercurrent Solvent Gradient Purification (MCSGP) technology marks a significant advancement in downstream processing for peptide and oligonucleotide manufacturing. Compared to traditional single-column batch purification, MCSGP reduces solvent consumption by over 30%, promoting greater sustainability. This process also offers higher capacity, achieving target product purity with yields that are typically 10% higher.
The automated system operates 24/7, enabling further reductions in cycle time. In 2021, Bachem acquired two process-scale MCSGP systems for High-Performance Liquid Chromatography (HPLC) and Anion Exchange Chromatography (AEX) purification, featuring 20 cm and 30 cm diameter columns. These systems are fully GMP-compliant, and large-scale purifications have been successfully conducted.
Figure 13: Process scheme of MCSGP (P = pure product; W = weakly adsorbing impurities; S = strongly adsorbing impurities; W/P = weakly adsorbing impurities overlapping with the product; P/S = product is overlapping with strongly adsorbing impurities). The numbers indicate theoretical steps in the process. The right part of the figure represents the UV profile of the feed injected into MCSGP.
At Bachem, we’re here to support your journey in the dynamic world of peptides. Explore career opportunities with Bachem and become part of a community of world-class professionals.
The peptide drug market has experienced significant growth in recent years and is expected to contin...
Manage Cookie Consent
Cookie Settings We use cookies so that we can offer you the best possible website experience. This includes cookies which are necessary for the operations of the website, as well as cookies that are only used for anonymous statistical purposes, for comfort settings or to display personalized content. Please note that based on your settings, it is possible that not all functionalities of the website will be available. You can find further information in our Privacy Policy
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.